Philips Appoints Medical Director to the Board of MDIC, a Partnership Organization with the FDA
Carla Goulart Peron, Medical Director at Royal Philips, has been appointed to the board of directors of the Medical Device Innovation Consortium (MDIC), a public-private partnership organization founded in 2012.
Carla Goulart Peron, MD, Chief Medical Officer at Philips, has been appointed to the board of directors of the Medical Device Innovation Consortium. In her current role at Philips, she leads the global medical and scientific organization of the group and oversees the company's medical strategy. Dr. Peron has over 15 years of experience as a leader in the medical technology industry and healthcare sector.
Role of the Medical Device Innovation Consortium
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The Medical Device Innovation Consortium brings together stakeholders from the medical device sector with the U.S. Food and Drug Administration (FDA) and other government partners. The organization develops research, tools, and frameworks of action designed to assist manufacturers in navigating regulatory approval and in building the necessary evidence base for coverage decisions. The MDIC board includes officials from the medical device industry, patient advocates, as well as representatives from the FDA, the Centers for Medicare and Medicaid Services (CMS), and the National Institutes of Health (NIH).
SectorSanté · Technologie · Dispositifs médicaux›Équipements Médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 3.9MD€
Free cash flow: 28M€
Guidance from the release
Nous avons délivré un bon départ en 2026.
Bonne performance au T1, croissance des ventes et des marges.
Risks mentioned
Impact des tarifs et inflation des coûts sur les marges.
Environnement macroéconomique incertain impactant les performances.
Opportunities identified
Croissance des ventes comparables de 4% dans tous les segments.
Augmentation du carnet de commandes grâce à des innovations.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.